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Abnormal expression and function of chromatin regulators results in the altered chromatin structure seen in cancer.
The chromatin regulator CTCF, its cofactor CHD8, and antagonistic paralogue BORIS have wide-ranging effects on
gene regulation. Their concurrent expression and regulation was examined in benign, localized, and metastatic
prostate cancer (PCa) arrays with extended follow-up using an automated quantitative imaging system, VECTRA.
Epithelial staining was quantified and compared against a range of clinicopathologic variables. CHD8 expression was
decreased in HGPIN, localized, andmetastatic PCa compared to benign (P b .001). CHD8 promoter hypermethylation,
assessed by Quantitative Pyrosequencing, occurred in over 45% of primary cancers in this population as well as the
TGCA database. Treatment of cell lines with the demethylating agent 5-Aza-2′-deoxycytidine reinduced expression. An
interesting dichotomy for CHD8 was observed within primary cancers, with higher nuclear protein expression
associated with adverse clinical outcomes including extracapsular extension (P= .007), presence of metastases (P=
.025) and worse PSA-recurrence free survival (P = .048). CHD8 outperformed Gleason score and predicted
biochemical failure within intermediate grade prostate cancers. The BORIS/CTCF expression ratio increased in
localized (P = .03) and metastatic PCa (P = .006) and was associated with higher Gleason score (P = .02), increased
tumor volume (P = .02) and positive margins (P = .04). Per cell heterogeneity of expression revealed all protein
expression to be more heterogeneous in cancerous tissue (both P b .001), especially high grade (P b .01). In the first
detailed analysis in cancer, a marked loss of CHD8 expression and increased BORIS/CTCF ratio indicate frequent
disruption of CTCF and its effector genes in PCa.
Neoplasia (2014) 16, 1018–1027Introduction
Prostate cancer (PCa) development is associated with epigenetic
changes seen in both aging normal and cancerous tissues [1]. The
factors that direct these changes remain elusive. Polycomb-group and
other proteins play a role in regulating genes through their
modification of chromatin structure. Recent data suggests a critical
role of these proteins, notably EZH2, in the malignant prostate
phenotype [2]. Three interrelated factors associated with the
regulation of epigenetic marks include Chromodomain helicase
DNA-binding protein 8 (CHD8), CCCTC-binding factor (CTCF),
and Brother of the regulator of imprinted sites (BORIS). CHD8 and
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through chromatin insulation, DNA methylation, and histone
acetylation [3]. Conversely, BORIS antagonizes CTCF function by
competing at CTCF binding sites [4,5]. Given the critical role of
these chromatin-regulating genes, the co-expression of these proteins
in PCa development and progression was investigated utilizing a
unique quantitative, per-cell expression analysis.
CTCF is an 11-zinc finger protein with multifaceted functions. In
addition to acting as a classical transcription factor, its presence
regulates chromatin structure and contributes to epigenetic homeo-
stasis through the formation of “boundary elements” between hetero-
and euchromatin [6]. With over 20,000 binding sites in the genome
its regulatory action is complex and depends on the specific DNA
sequence and interacting factors at CTCF binding sites [7]. CTCF
loss of function epigenetically alters numerous cancer-associated
genes. In various cancers lack of CTCF activity is associated with
epigenetic repression of hTERT, pRb, p16INK4A, p14ARF, and p53
[7]. As a chromatin insulator, CTCF is known to have enhancer-
blocking activity as demonstrated in the imprinted Igf2-H19 imprint
control region [8]. Its function is opposed by its paralogue BORIS,
also known as CTCFL, that has extensive homology to the CTCF
DNA-binding motif [9]. While CTCF is known to protect and
maintain DNA methylation marks, BORIS expression coincides with
the loss of CpG methylation [4,10,11]. Their antagonistic function is
seen at theMAGE A1 promoter, where CTCF acts as a transcriptional
repressor and BORIS leads to gene activation [5]. BORIS may
function as an oncogene and recent reports suggest its reactivation
occurs in a variety of cancers, including the prostate [12].
The chromatin insulator function of CTCF is dependent on
CHD8, an ATP-dependent chromatin remodeling enzyme [3,13].
CHD8 co-localizes and interacts with CTCF at several gene insulator
sites including the Igf2-H19 differentially methylated region (DMR),
B-globin 5′HS5 insulator, and the c-myc and BRCA1 gene promoters.
The presence of both factors is required for normal genetic and
epigenetic regulation [3]. CHD8 is a target in gastric and colorectal
cancers [14]. The CHD8-CTCF complex prevents the spread of
transcriptionally inactive heterochromatin and a loss of CHD8 results
in DNA hypermethylation and histone hypoacetylation near CTCF
binding sites [3]. Functional studies of CHD8 have shown
dichotomous roles with regard to cell cycle activity. The presence
of CHD8 negatively regulates β-catenin signaling, suppresses p53-
dependence [15,16], and negatively regulates HOXA2 gene
expression [17]. Conversely, CHD8 cooperates with androgen
receptor to activate TMPRSS2 and is implicated in E2F-dependent
gene transcription [18,19]. The literature suggests a complex, and
cryptic, role for CHD8 where losses and gains of function could have
oncogenic-like gene regulation properties.
To analyze expression synchronously the VECTRA imaging system
was employed, a quantitative tool which allows the automated
selection and analysis of expression signals within cells, cellular subsets,
and compartments. This study sought to investigate the compart-
mental coexpression of these proteins and their clinical significance in
PCa. These analyses reveal significant decreases in CHD8, in part due
to hypermethylation, and increases in BORIS-CTCF ratio in PCa
development. However, a dichotomy of higher CHD8 expression is
associated with adverse features, including increased risk of PSA
recurrence. Using this powerful imaging tool, we find the CTCF
regulatory pathway is frequently altered in PCa which may help to
explain common changes in CTCF effector genes in cancer.Methods
Tissue Microarray
The University of Wisconsin Institutional Review Board (IRB)
provides ethical insight to clinical projects and reviews all human
research protocols in accordance with federal regulations, state laws,
and local and University policies. FFPE-patient tissues used in this
study were from the archive of the Department of Pathology and
Laboratory Medicine, University of Wisconsin-Madison. A tissue
microarray was constructed consisting of 288 duplicate cores from
prostate tissues of different disease groups: 48 benign prostate tissues
(BPT) (from normal, non-adjacent tissue without evidence of
disease), 50 high grade intraepithelial neoplasia (HGPIN) (tissue
from HGPIN tissue blocks of cancer patients in this cohort), 84
localized PCa (pT2), 62 aggressive PCa (pT3), and 44 metastatic
lesions (brain, lung, bone, omentum, testis, colon, bladder, and
lymph nodes).
Staining and Image Analysis
Slide preparation and antigen retrieval were conducted as
previously described [20]. Briefly, the slides were taken through
routine deparaffinization and rehydration. Two triple stains (CTCF,
CHD8, and E-cadherin; CTCF, BORIS, and E-cadherin) were
performed from two TMA sections with antibodies against CTCF
(sc-5916; Santa Cruz Biotech, Santa Cruz, CA), CHD8 (NB100-
60418; Novus Biologicals, Littleton, CO), and BORIS (sc-98982
Santa Cruz Biotech, Santa Cruz, CA). E-cadherin antibodies (Cell
Signaling Technology, Beverly, MA) were used to define the epithelial
compartment for better tissue segmentation.
Stained slides were loaded onto the slide scanner. Slides were
scanned as previously described [20]. Cores with b5% epithelial
component or loss of tissue were excluded from the analysis. Per-cell
protein target signals were quantitated for individual cores using the
VECTRA imaging system according to manufacturer's protocols
(Caliper Life Sciences, Hopkinton, MA). The inForm 1.2 software
was used to segment tissue subcellular compartments (nucleus vs.
cytoplasm) and tissue compartments (epithelium vs. stroma).
Methylation Analysis of CHD8 in Human Prostate Tissues
We obtained 11 paired flash frozen samples of tumor and benign
adjacent tissue from radical prostatectomy samples using an approved
IRB protocol. DNA was generated and Quantitative Pyrosequencing
was employed as we have previously described [21], to assess
methylation across 2 CpG island regions previously suggested to be
altered on methylation arrays [22]. These regions were: i) 6 CpGs
spanning the transcription start site (TSS) of CHD8 [Chr14:21,907,003-
21,906,863] and ii) 7 CpGs encompassing a CpG island 600 bp upstream
of the transcription start site [Chr14:21,907,850-21,907,725]. Primers are
available upon request.Methylation Validation in The Cancer Genome Atlas Samples
To verify the patterns of methylation observed in cancer samples
data was downloaded and analyzed form The Cancer Genome Atlas
(TCGA) Project (https://tcga-data.nci.nih.gov/tcga/). The dataset
contained methylation information for 49 solid prostate tissue normal
(benign) and 336 prostate adenocarcinoma samples analyzed by the
Illumina HumanMethylation450k Array. This dataset included
information on the 6 CpGs analyzed at the CHD8 TSS, the 7
CpGs 600 bp upstream were not analyzed by the 450 k Array.
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in Cell Lines
A panel of cells was screened for low expression of CHD8. Two
prostate cancer cell lines (DU145 and LNCaP) and Hela were treated
with increasing doses of 5-Aza-2′-deoxycytidine (0 to 100 μM) for 48
hours, RNA was isolated and Quantitative PCR was performed as
previously described [21]. Briefly, CHD8 expression was analyzed by
quantitative PCR using a CFX96 real-time PCR detection system
(Bio-Rad) and SYBR Green PCR master mix (Applied Biosystems).
Primers used as previously described [23]. Results were statistically
compared using the t-test. DNA was generated, bisulfite treated, and
Quantitative Pyrosequencing performed analyzing the same regions
as the human prostate tissues above.
Statistical Analysis
Nuclear, cytoplasmic, and total expression of individual cores of
various prostate tissues (benign, HGPIN, PCa, metastatic PCa) was
statistically compared using Kruskal-Wallis test followed byWilcoxon
rank-sum tests. Pearson's r correlation analysis was used to quantify
the relationship between CHD8/CTCF and BORIS/CTCF expres-
sions. To compare protein expression in patient cancer samples with
different clinicopathologic features (Gleason, pT stage, tumor
volume, margins, SV involvement, extracapsular extension, and
evidence of metastasis), Kruskal-Wallis test or Wilcoxon rank-sum
test was used as appropriate, only primary tumor samples were used in
this analysis. Duplicate PCa cores obtained from the same patient (73
cases) were averaged to provide a more precise estimation of protein
expression in each biological replicate. Protein expression from 6
patients without clinical data was excluded from clinicopathologic
analysis. Thus, 67 primary cancer patients in total were included in
the clinicopathologic analysis after quality controls (Patient demo-
graphics, Table S1).
The spread and shape of per cell protein expressions for various
tissues were characterized by calculating the coefficient of variation,
skewness, and kurtosis. Further, these values were compared among
varying pathological grades using the same non-parametric tests as
described above. The Simpson's Diversity Index (Gini-Simpson
transformation) [24] was used to analyze heterogeneity as
outlined by Faratian et al. [25]. Briefly, per cell expression data
of all samples was used to derive bins of equal percentages.
Binning continuous expression values yield a score for each cell.
Each cell from each core was then applied to the Gini-Simpson
Index of diversity defined as:
SI ¼ 1−
X
n n−1ð Þ
N N−1ð Þ
Where n is the score of each binned cell and N is the total number
of cells in each core. The SI scores for each core were then used to
generate average diversity scores of Benign, HGPIN, localized PCa,
and metastatic PCa.
Results
CHD8 Expression is Commonly Decreased in Localized and
Metastatic PCa
The CTCF-CHD8 (BORIS) system was synchronously investi-
gated given their associations (Figure 1A) using the VECTRA
imaging system which allows the automated selection and analysis of
cells, cellular subsets (epithelial vs. stromal) and subcellularcompartments (nucleus vs. cytoplasm). Nuclear levels of CHD8
were 1.5 to 2.5 fold higher than cytoplasmic in all samples. Total,
nuclear, and cytoplasmic expression of CHD8 was significantly
decreased in HGPIN, metastatic lesions, and primary PCa compared
to benign prostate tissue (Figure 1B) (all P b .001, HGPIN
cytoplasmic not significant). To define reduced expression, a Receiver
Operating Curve (ROC) was constructed using total CHD8
expression to identify the optimal cut point that maximized the
sum of sensitivity and specificity for discriminating between benign
versus cancer cores. ROC analysis demonstrated excellent discrim-
ination between benign versus cancer (AUC 0.866, P b .0001) with a
sensitivity and specificity of 84.3% and 76.3% respectively
(Figure 1C ). Using the optimal cut-off of 0.065 to define decreased
core expression, 118/140 (84.3%) of localized PCa, 18/46 (39.1%) of
HGPIN, and 29/39 (74.4%) of metastatic lesions demonstrated
reduced expression of CHD8 in contrast to only 19/80 (23.8%) of all
benign cores (Figure 1D). Therefore, decreased CHD8 expression is a
common finding in PCa tissues.
Analysis of CHD8 Promoter-Associated CpG Hypermethylation
in Human Prostate Tumor Samples
CHD8 contains a promoter CpG island making CHD8 promoter-
associated hypermethylation one etiology for the decreased expression.
One region spanning the CHD8 transcription start site (TSS) and
another region 600 bp upstream were analyzed. At the region 600 bp
upstream high levels of equivalent methylation was seen in all tumor
and benign samples (data not shown). At the TSS CpG island, 5/11
(45%) of tumor samples demonstrated increased methylation across the
first 4 CpG sites compared to benign (Figure 2A). To further assess this
finding, we assessed methylation using 366 primary prostate tumors
within the TGCA database. A significant increase in methylation across
CpG 1 to 4 was also seen when tumor and normal tissues were
compared (Wilcoxon Rank-sum all P b .001)(Figure 2B). In this
validation dataset, 55%-67% of tumors showed increased methylation
(compared to benign tissue mean) at CpGs 1 to 4 (data not shown).
To assess the role of methylation in controlling CHD8
transcription, a panel of cell lines was analyzed for CHD8 expression.
Cell lines with lower expression of CHD8 were treated with
increasing doses of 5-aza-2′-deoxycytidine (5-azadC) for 48 hrs prior
to harvesting. 5-azadC resulted in a dose-dependent increase in
CHD8 expression compared to DMSO alone (all P b .05) for
LNCaP (Figure 2C ) and Hela (data not shown) cell lines. Similar
treatment of DU145 did not result in increased expression of CHD8
mRNA (data not shown). Analysis of CHD8 CpGmethylation across
the TSS showed similar levels of methylation across all 3 cell types
(Figure S1A). Additionally, all three cell types were highly methylated
at a region 600 base pairs upstream of the TSS (Figure S1B). These
data indicate that DNA hypermethylation is a common finding
within the CHD8 promoter region and treatment with a
demethylating agent results in increased CHD8 expression.In Primary Tumor Samples, Increasing CHD8 Expression is
Associated with Adverse Clinical Features and Outperforms
Gleason Score in Predicting PSA Recurrence in Intermediate
Grade Tumors
CHD8 expression was compared against a series of clinicopathologic
variables including Gleason score, tumor stage, tumor volume, seminal
vesicle involvement, positive margins, extracapsular extension and the
presence of metastases (Table 1). UsingCHD8 as a continuous variable,
Figure 1. Quantitative analysis of CHD8 expression. Using the VECTRA automated image capture and analysis nuclear, cytoplasmic and
total compartments were compared. Mean intensity of cores were compared for benign, HGPIN, cancer, and metastases with 95%
confidence intervals. (A) Demonstrates the interactions of BORIS, CTCF, and CHD8; where BORIS and CTCF compete for similar binding
sites, and CTCF and CHD8 complex at CTCF binding sites. (B) Significant decreases in CHD8 expression are seen in cancer and
metastases cores for total, nuclear, and cytoplasmic expression (P b .001, cytoplasmic HGPIN not significant). (C) Total CHD8 expression
demonstrated optimal discrimination between benign and cancer (AUC = 0.866, P b .0001) by ROC analysis, with a sensitivity and
specificity of 84.3% and 76.3%. (D) Using the optimum cut-off obtained by ROC analysis, 84.3% of cancer and 74.4% of metastases
cores demonstrated decreased CHD8.
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extracapsular extension (P =.021 and P = .007 respectively) and
metastases (P = .037 and P = .025 respectively) (Table 1). The analyses
did not find any associations between Gleason score or tumor volume
and CHD8 expression.
Generating molecular predictors of treatment failure, especially
within intermediate grade cancers is a pressing clinical need. An analysis
of PSA recurrence after prostate removal, which indicates treatment
failure, was performed. Patients with increased CHD8 expression
exhibited an earlier PSA recurrence (P = .048) (Figure 3A). Gleason
score provides weak separation of patients into risk categories for PSA
recurrence (P = .163) (Figure 3B). Stratifying intermediate Gleason
patients by CHD8 expression shows that patients with higher CHD8
expression had a greater risk of biochemical recurrence (P = .048)
(Figure 3C). Therefore, although decreased in cancer compared to
benign, increasing CHD8 levels in cancer cores are associated with
adverse clinicopathologic variables and worse outcomes.
BORIS/CTCF Expression Ratio is Increased in Cancer Samples
and Correlates with Higher Gleason Score
CTCF is known to impact gene regulation through the
management of chromatin organization and the maintenance ofepigenetic marks [26]. CTCF expression levels measured by VECTRA
were significantly decreased in metastatic PCa tumors (P b .001), but
not localized PCa when compared to benign prostate tissues (P = .17)
(Figure 4A). When CTCF expression within primary tumors was
compared against clinicopathologic patient variables, decreased
nuclear and total CTCF expression was associated with higher
Gleason's Score (P = .01 and P = .001 respectively) and positive
margins (P = .03 and P = .043 respectively) (Data not shown).
The CTCF paralogue, BORIS, shares a common zinc-finger
DNA-binding domain with divergent N- and C- termini. BORIS and
CTCF have competing effects on gene expression and epigenetic
regulation [5,27]. In contrast to CTCF, BORIS expression was
increased in HGPIN and primary cancer cores compared to benign
(P b .001 and P = .002 respectively) (Figure 4B). No clinicopath-
ologic correlates were noted.
The competing role for BORIS/CTCF suggests the ratio of their
expression may contain functional significance and greater predictive
power than the expression of these proteins individually as seen in
ovarian cancer [28]. Analyzing all prostate tissues, a weak correlation
was seen between BORIS and CTCF (Pearson's r = .224, P b .001).
BORIS/CTCF levels increased significantly in cancer and metastases
compared to benign (P = .03 and P = .006 respectively) (Figure 4C ).
Figure 2. Methylation analysis of CHD8 in human PCa and 5-Aza-2′-deoxycytidine treatment of cancer cell lines. DNA methylation was
analyzed by Quantitative Pyrosequencing across the CHD8 transcriptional start site. (A) Hypermethylation of CHD8 promoter-associated
CpGs 1 to 4was seen in 5/11 (45%) human tumor samples compared tomatched benign. (B) Significant hypermethylationwas seen at 4/6 of
the promoter-associated CpGs in tumors compared to benign in TCGA PRAD samples (methylation 450 K array) (All P b .001). (C) 5-azadC
treatmentof LNCaP cells for 48 hours resulted in a 1.5- to 2.5-fold significant increaseofCHD8mRNAover treatment vehicle alone (allPb .05).
Table 1. Association of CHD8 Expression With Patient Pathological Features.
Variable Number Nucleus Cytoplasm Total
Mean Intensity (SD) p-value Mean Intensity (SD) p-value Mean Intensity (SD) p-value
Gleason *
3 + 3 or 3 + 4 38 3.80 (0.71) 0.209 1.81 (0.47) 0.589 5.61 (1.12) 0.256
4 + 3/4 + 4/4 + 5 28 3.54 (0.77) 1.75 (0. 54) 5.28 (1.27)
Stage
T2 39 3.54 (0.64) 0.054 1.68 (0.39) 0.132 5.22 (0.99) 0.064
T3 11 3.73 (0.84) 1.95 (0.68) 5.68 (1.49)
T4 17 4.19 (0.78) 1.98 (0.50) 6.16 (1.20)
Tumor Volume
b5 9 3.74 (0.42) 0.891 1.73 (0.46) 0.745 5.48 (0.84) 0.987
5-20 31 3.65 (0.93) 1.71 (0.52) 5.36 (1.40)
N20 24 3.68 (0.75) 1.83 (0.53) 5.51 (1.24)
SV involvement
Absent 48 3.57 (0.71) 0.10 1.68 (0.42) 0.088 5.26 (1.09) 0.089
Present 15 4.04 (0.96) 2.06 (0.71) 6.10 (1.60)
Margins Positive
No 42 3.76 (0.62) 0.119 1.84 (0.48) 0.044 5.60 (1.05) 0.085
Yes 24 3.51 (1.01) 1.63 (0.56) 5.14 (1.52)
Extracapsular
No 42 3.47 (0.73) 0.007 1.66 (0.46) 0.0622 5.14 (1.15) 0.021
Yes 23 4.04 (0.76) 1.95 (0.57) 5.99 (1.27)
Metastasis †
No 50 3.59 (0.69) 0.025 1.75 (0.49) 0.111 5.34 (1.14) 0.037
Yes 16 4.19 (0.78) 1.98 (0.50) 6.16 (1.20)
* One patient GS 3 + 5 not analyzed.
† Metastasis refers to primary tumor samples with associated metastases.
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Figure 3. KaplanMeier analyses comparing pathological Gleason Score versus CHD8. Biochemical recurrence after radical prostatectomy
was examined in patient samples stained for CHD8. (A) Nuclear CHD8 significantly separates patients into risk categories for PSA
recurrence using a Log rank analysis (P= .048). (B) Gleason score provides insignificant separation of patients for PSA recurrence using a
Log rank analysis (P = .163). (C) Nuclear CHD8 is superior to pathological Gleason score when Gleason score was stratified into low
versus high CHD8. The median value for nuclear CHD8 staining was 0.04025 in all benign and cancer samples. This value was
subsequently used as a cut point to define high versus low nuclear CHD8 expression for the Log rank analysis.
Neoplasia Vol. 16, No. 12, 2014 Damaschke et al. 1023High Gleason cancers have a significantly greater BORIS/CTCF ratio
than both benign tissues and intermediate Gleason cancers (P = .006
and P = .024 respectively) (Figure 4D). The ratio of nuclear and total
expression was calculated and found to be associated with Gleason's
grade, positive surgical margins, and tumor volume (nuclear P = .024,
P = .027, P = .020, respectively) (Table 2, for full table see
supplementary data, Table S2).
Exclusion of CHD8 and/or BORIS Alterations is Seen in a
Majority of Cancers
Our analysis permits a comparison of the expression of each of the
chromatin regulators in the CTCF/CHD8/BORIS pathway within
specific tumors. We speculated that inactivation of one gene in this
pathway might exclude alterations in the other related genes in the
CTCF complex. To first test this, the cBioPortal for Cancer Genomics
(www.cbioportal.org/public-portal/) was queried for alterations in
these 3 genes and the CTCF/CHD8/BORIS pathway was genetically
altered in 15% of PCa (Table S3). Similar low rates of concurrent
alteration were seen in other cancers. This included amplification of
BORIS, homozygous deletion of CTCF, and mutation of CHD8.We
extended this analysis to our data by segregating gene expression into
quartiles in the entire dataset using all cores (benign, HGPIN, cancer,
and metastases). Expression alterations in CTCF were rarely seen andthus were not analyzed. Segregating all 73 patient tumor samples from
our data into expression quartiles we found 26/73 (36%) exhibit
decreased and 8/73 (11%) exhibit increased CHD8. Analyzing
BORIS expression, 19/73 (26%) exhibit increases and 7/73 (10%)
show decreased expression. Expressional alterations occurred in 51/73
(70%) of the tumors in total (Figure 5A). Comparatively, alterations in
both genes were rarely seen (9/73; 12%%). Odds ratio analysis
indicated that these alterations showed a tendency toward mutual
exclusivity (OR, 0.46).
CTCF, BORIS, and CHD8 Expression is Significantly More
Heterogeneous in Higher Grade Cancers
The majority of human tumors display startling heterogeneity in
many morphological and physiological features, but the ability to
objectively quantitate this aspect has been lacking. VECTRA was
utilized to assess per cell expression within benign and tumor cores
and heterogeneity scores for each core was calculated using the
Simpson's Diversity Index (SI), a formula generally used in the
population sciences [24]. The SI uses population size to normalize
diversity analyses to a uniform scoring system for comparison. SI
analyses revealed BORIS, CHD8, and CTCF all demonstrate
increased heterogeneity of protein expression in primary cancer and
metastases compared to benign (all P b .001) (Figure 5, B–D
Figure 4. Quantitative analysis of CTCF and BORIS expression in human PCa. (A) Nuclear CTCF significantly decreases in metastases
cores (P b .001) (B) BORIS nuclear expression significantly increased in cancer cores (P = .002); nuclear and cytoplasmic expression
increased in HGPIN cores compared to benign (both P b .001). (C) The ratio of BORIS to CTCF expression was analyzed for differences
among cores. Significant increases in the BORIS/CTCF ratio are seen among cancer and metastases cores compared to benign (P= .031
and P = .006 respectively). (D) Comparing the BORIS/CTCF ratio among cancer cores, high Gleason grade cancers have significantly
higher BORIS/CTCF ratio than both benign and intermediate Gleason cores (P = .006 and P = .024 respectively).
1024 Chromatin Factors Altered in Prostate Cancer Damaschke et al. Neoplasia Vol. 16, No. 12, 2014respectively). Within primary PCa cores, increased heterogeneity was
also seen in higher grade cancer (CHD8, P = .001, CTCF P b .001,
and BORIS, P = .001). Similar increased heterogeneity was seen
when the coefficient of variation was calculated for these proteins
(data not shown).Table 2. Association of BORIS/CTCF Expression Ratios with Patient Pathological Features.
Variable Number Nucleus
Mean Intensity (SD) p-value
Gleason *
3 + 3 or 3 + 4 38 1.22 (0.41) 0.024 *
4 + 3/4 + 4/4 + 5 28 1.53 (0.64)
Tumor volume
b5 9 0.96 (0.38) 0.020 *
5-20 31 1.38 (0.67)
N20 24 1.36 (0.42)
Margins positive
No 42 1.23 (0.42) 0.027 *
Yes 24 1.56 (0.69)
* One patient GS 3 + 5 not analyzed.Discussion
CTCF is a transcriptional regulator and member of the BORIS and
CTCF gene family. It has well known insulator activity where
binding to a transcriptional insulator element serves to block
enhancer-promoter interactions [29] and can also act as a classicalCytoplasm Total
Mean Intensity (SD) p-value Mean Intensity (SD) p-value
2.96 (1.21) 0.019 * 1.59 (0.54) 0.021 *
3.88 (2.06) 2.03 (0.93)
2.28 (0.89) 0.029 * 1.25 (0.49) 0.022 *
3.35 (2.13) 1.82 (0.97)
3.54 (1.38) 1.81 (0.58)
3.12 (1.31) 0.204 1.63 (0.56) 0.041 *
3.78 (2.24) 2.06 (1.00)
Figure 5. CHD8 andBORIS expression alterations are exclusive and exhibit significantly greater heterogeneity inmalignant cores. (A) Using
expression of all cores, the expression data for CHD8 and BORIS was divided into quartiles. Each column box-pair represents a primary
tumor sample (total 73). When cancer cores are separated into quartiles of protein expression, CHD8 is frequently decreased (26/73; 36%)
while BORIS is frequently increased (19/73; 26%) in primary cancer. Rare cancers (12%) exhibited both alterations in concert indicating that
these pathway alterations infrequently occur in concert. An analysis of heterogeneity of cores was performed using the Simpson's
Diversity Index (SI). BORIS (B), CHD8 (C), and CTCF (D) all had significantly higher heterogeneity of protein expression in cancer and
metastases cores compared to benign (all P b .005) as measured by Simpson's Diversity Index.
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epigenetic regulation including many cell cycle and cancer specific
genes [7,10]. The function of CTCF is modulated at a number of
levels, including at the protein level by cofactors and competitive
inhibitors. This study analyzed the synchronous expression of CTCF,
its cofactor CHD8, and the antagonistic CTCF paralogue BORIS
using VECTRA imaging technology. Increased heterogeneity in
higher grade cancers was found and the coexpression of these
chromatin regulators was largely independent of each other. A striking
decrease in CHD8 expression is a major finding in the majority of
primary PCas and metastatic deposits. An interesting contrast in
CHD8 expression was also discovered with increased levels being
associated with more adverse clinical variables and PSA recurrence-
free survival. BORIS/CTCF levels also correlated with worse
pathologic variables. This unique approach suggests a significant
role for alterations in these chromatin factors in PCa.
There has been increased interest in the CHD family [13,14] given
the finding of inactivation of other family members in disease
including the recent findings of somatic mutation of CHD5 [31] and
deletion of CHD1 [32]. CHD8 exhibits a functional dichotomy
operating in both growth inhibitory and promoting roles including
chromatin remodeling, WNT signaling, CTCF insulator activity,
p53-mediated apoptosis, androgen receptor mediated gene activity,
and regulation of cell cycle genes [33]. In the current study, the
expression of CHD8 significantly decreased in HGPIN, cancer, and
metastases compared to benign tissue. Using a cut-off determined by
ROC analysis maximizing sensitivity and specificity, 84% of localized
and 74% of metastatic PCa tumors exhibited decreased CHD8
expression. One potential significant implication of decreased CHD8may be a loss of the CTCF-CHD8 complex, which serves to stabilize
regulation of CTCF effector genes. Ishihara et al. found losses of
CHD8 altered DNA methylation and histone acetylation around
CTCF binding sites, adjacent to heterochromatin, in HeLa and
hepatoma cell lines [3].
An interesting dichotomy of expression was discovered using
imaging analysis. In tumor tissues, increased CHD8 expression was
associated with the presence of metastases and extracapsular extension
(Table 1). Extending this analysis to examine risk of PSA recurrence
after radical prostatectomy, we found that CHD8 expression served
to discriminate between indolent intermediate grade cancers and
those at higher risk of recurrence. Markers that predict a worse
outcome for intermediate grade cancers are an area of intense clinical
interest. The dichotomy in expression suggests a loss of function is
important for cancer development, but progression is facilitated by
higher expression. Alternatively, higher levels seen with cancer
progression may indicate a nonfunctional or altered protein.
Loss of CHD8 may alter CTCF function, as well as aberrant
expression of the CTCF paralogue and cancer-testis antigen BORIS.
We found BORIS expression to be significantly increased in cancer
compared to benign prostate tissues. Recently published findings in
prostate tumor tissues and cell lines support this observation [12].
The identical 11-zinc finger DNA-binding domains of CTCF and
BORIS may result in sibling rivalry for binding sites but their
divergent amino- and carboxy-terminal domains result in antagonistic
gene regulation functions [11]. Exploiting this competition, a recent
study in ovarian cancer found BORIS/CTCF ratio of expression levels
correlate with advanced stage and DNA hypomethylation levels [28].
An analysis of the ratio of BORIS/CTCF expression in prostate
1026 Chromatin Factors Altered in Prostate Cancer Damaschke et al. Neoplasia Vol. 16, No. 12, 2014cancer demonstrated a significant increase in cancer that correlated
with higher Gleason's grade, positive surgical margins, and increased
tumor volume. Aberrant BORIS expression may work alternatively or
in concert with CHD8 decreases to disrupt CTCF action within
the genome.
Our analysis permits a comparison of expression of each of the
chromatin regulators in the CTCF/CHD8/BORIS pathway within
specific tumors. By investigating the highest or lowest quartiles of
expression we determined that CHD8 down-regulation and BORIS
up-regulation occurred commonly in 56% of tumors analyzed.
Furthermore, decreased CHD8 expression rarely occurred with
BORIS amplification (Figure 5A). The mechanisms underlying
CTCF deregulation in disease are complex and include loss of
heterozygosity, mutation, post-translational modification, and meth-
ylation at CTCF target sites. Using the cBioPortal, a similar tendency
for multiple tumor types (breast, ovarian, uterine, colon) that
demonstrate BORIS amplification to not contain alterations in
CTCF or CHD8 was seen, suggesting if one component of the
pathway is altered, others are not required (Table S2).
We performed an analysis of CHD8 TSS hypermethylation and
find this occurs in roughly 45% of tumors examined. TCGA cohorts
analyzed revealed that four of the six CpGs analyzed are significantly
hypermethylated in tumor samples. This confirms data seen in a
recent high-throughput methylation array analysis of prostate tumors
[22]. Treatment of cancer cell lines with a methyltransferase inhibitor
(5-azadC) resulted in increased expression of CHD8 mRNA in
LNCaP indicating DNA methylation plays a role in CHD8
regulation (Figure 2C). Other mutational events or epigenetic
marks, such as histone modifications, may also play a role in reducing
CHD8 expression. Therefore, epigenetic silencing of CHD8 may be
one mechanism for alterations of expression.
Tumor development can be regarded as a process of Darwinian
evolution. Selection forces required for the emergence of malignancies
and increase genetic and epigenetic instability generate clonal
populations. The VECTRA analysis platform is a powerful objective
tool for analyzing patterns of protein expression in tissues. To
capitalize on this extensive quantitation we used per cell data to
analyze the heterogeneity of protein expression in tissue cores. The
coefficient of variation and the Simpson's Diversity Index, a measure
originally developed to measure ecological diversity, were applied to
capture this aspect. We find PCa cores contain increased heteroge-
neity for all proteins. In addition, cancers with higher Gleason score
are significantly more heterogeneous. This suggests that heterogeneity
of expression translates into phenotypic diversity; this may be a
potential biomarker in the future.
In conclusion, we demonstrate for the first time that CHD8
expression is frequently altered in PCa and its expression more
accurately predicts PSA-recurrence with Gleason score over Gleason
score alone. Interestingly, CHD8 is decreased in cancer, however
higher expression is seen with more adverse clinical features. This
dichotomy may be explained, in part, by the diverse functions of
CHD8. The use of imaging technology allows a number of novel
observations to be performed. The higher heterogeneity of protein
expression seen in cancer and metastases may convey plasticity in
CHD8 expression. Early decreases in CHD8 may conceivably be
advantageous to tumor development, while tumor progression
involves a subsequent shift to higher CHD8 within the tumor.
Changes in CTCF/BORIS may accompany CHD8 expressional
alterations, further contributing to neoplastic development. Frequentalterations of the CHD8/CTCF/BORIS pathway suggest a crucial
function in early PCa development. Biologically, this pathway affects
chromatin and epigenetic regulation [3,10], key factors in early
neoplasia. These findings warrant future study of the functional
consequences of CHD8, CTCF, and BORIS expression alterations in
the prostate.
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